Nifty
:
24398.70
Sensex
:
78180.72
-31.65 (-0.13%)
-104.35 (-0.13%)
Nifty
Sensex
:
:
24398.70
78180.72
-31.65 (-0.13%)
-104.35 (-0.13%)

Piramal Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
52/99

BSE: 543635 | NSE: PPLPHARMA

NSE BSE
175.23
07-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  179
  •  180.35
  •  174.4
  •  177.88
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5073248
  •  897295302.15
  •  220.85
  •  132.3

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 23,311.91
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 27,583.75
  • N/A
  • 2.88

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.86%
  • 1.12%
  • 13.74%
  • FII
  • DII
  • Others
  • 30.17%
  • 15.36%
  • 4.75%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.22
  • 2.77

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -1.23
  • -5.28

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.75
  • 21.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 2.91

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 20.71

Earnings Forecasts:

(Updated: 04-07-2026)
Description
2026
2027
2028
2029
Adj EPS
39
2
125.58
-1.3
P/E Ratio
4.49
87.62
1.40
-134.79
Revenue
102.04
41.92
26.35
8945.49
EBITDA
10079.1
11502.5
12946.3
950.33
Net Income
1374.84
1888.46
2279.37
-162.79
ROA
219.9
531.94
845.96
1.4
P/B Ratio
0.04
0.04
0.04
2.86
ROE
2.66
2.5
2.25
-1.19
FCFF
2.88
5.88
7.96
423.83
FCFF Yield
65.01
506.5
773.4
1.59
Net Debt
0.24
1.9
2.89
4158.1
BVPS
4410.8
4241.13
4015.07
61.34

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
2,751.77
2,754.07
-0.08%
2,139.87
2,204.22
-2.92%
2,043.72
2,241.75
-8.83%
1,933.71
1,951.14
-0.89%
Expenses
2,291.26
2,193.08
4.48%
1,944.14
1,866.48
4.16%
1,885.03
1,900.14
-0.80%
1,827.01
1,746.65
4.60%
EBITDA
460.51
560.99
-17.91%
195.73
337.74
-42.05%
158.69
341.61
-53.55%
106.70
204.49
-47.82%
EBIDTM
16.73%
20.37%
9.15%
15.32%
7.76%
15.24%
5.52%
10.48%
Other Income
46.06
42.03
9.59%
43.24
12.13
256.47%
65.60
61.11
7.35%
58.40
19.54
198.87%
Interest
82.99
103.68
-19.96%
89.24
103.31
-13.62%
82.42
107.64
-23.43%
86.15
106.96
-19.46%
Depreciation
218.38
242.76
-10.04%
212.74
196.81
8.09%
202.84
192.22
5.52%
197.28
184.55
6.90%
PBT
29.43
256.58
-88.53%
-104.12
49.75
-
-60.97
102.86
-
-97.59
-67.48
-
Tax
51.83
119.30
-56.55%
42.33
63.12
-32.94%
53.04
97.53
-45.62%
2.68
43.56
-93.85%
PAT
-22.40
137.28
-
-146.45
-13.37
-
-114.01
5.33
-
-100.27
-111.04
-
PATM
-0.81%
4.98%
-6.84%
-0.61%
-5.58%
0.24%
-5.19%
-5.69%
EPS
-0.07
1.16
-
-1.03
0.03
-
-0.75
0.17
-
-0.62
-0.67
-

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
-
8,869.08
9,151.18
8,171.16
7,081.55
6,559.10
6,314.90
Net Sales Growth
-
-3.08%
11.99%
15.39%
7.97%
3.87%
 
Cost Of Goods Sold
-
3,238.54
3,231.65
2,954.00
2,703.30
2,451.26
2,059.11
Gross Profit
-
5,630.54
5,919.53
5,217.16
4,378.25
4,107.84
4,255.79
GP Margin
-
63.49%
64.69%
63.85%
61.83%
62.63%
67.39%
Total Expenditure
-
7,976.59
7,733.31
7,000.65
6,453.31
5,609.44
4,886.94
Power & Fuel Cost
-
260.18
267.16
241.59
207.81
163.56
136.70
% Of Sales
-
2.93%
2.92%
2.96%
2.93%
2.49%
2.16%
Employee Cost
-
2,415.92
2,307.47
2,029.50
1,896.35
1,588.83
1,467.74
% Of Sales
-
27.24%
25.21%
24.84%
26.78%
24.22%
23.24%
Manufacturing Exp.
-
808.39
774.18
731.64
674.10
589.03
544.09
% Of Sales
-
9.11%
8.46%
8.95%
9.52%
8.98%
8.62%
General & Admin Exp.
-
592.71
563.04
542.00
472.78
428.49
367.25
% Of Sales
-
6.68%
6.15%
6.63%
6.68%
6.53%
5.82%
Selling & Distn. Exp.
-
437.58
398.11
359.75
372.59
317.81
250.16
% Of Sales
-
4.93%
4.35%
4.40%
5.26%
4.85%
3.96%
Miscellaneous Exp.
-
223.27
191.70
142.17
126.38
70.46
61.89
% Of Sales
-
2.52%
2.09%
1.74%
1.78%
1.07%
0.98%
EBITDA
-
892.49
1,417.87
1,170.51
628.24
949.66
1,427.96
EBITDA Margin
-
10.06%
15.49%
14.32%
8.87%
14.48%
22.61%
Other Income
-
242.43
161.77
201.14
225.11
275.80
164.11
Interest
-
340.80
421.59
448.49
344.18
198.25
163.45
Depreciation
-
831.24
816.34
740.57
676.69
586.18
545.04
PBT
-
-37.12
341.71
182.59
-167.52
441.03
883.58
Tax
-
149.88
323.51
161.47
66.31
109.02
114.02
Tax Rate
-
-64.25%
94.67%
134.78%
-38.00%
25.59%
12.64%
PAT
-
-325.94
91.13
17.82
-186.46
375.96
835.03
PAT before Minority Interest
-
-325.94
91.13
17.82
-186.46
375.96
835.03
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
-3.68%
1.00%
0.22%
-2.63%
5.73%
13.22%
PAT Growth
-
-
411.39%
-
-
-54.98%
 
EPS
-
-2.45
0.69
0.13
-1.40
2.83
6.28

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
8,162.62
8,125.47
7,911.37
6,773.50
6,696.60
5,605.00
Share Capital
1,327.16
1,324.35
1,322.95
1,193.32
1,185.91
994.60
Total Reserves
6,762.67
6,738.96
6,560.95
5,580.18
5,510.69
4,610.30
Non-Current Liabilities
4,529.41
3,392.72
2,644.64
3,812.00
2,902.58
2,560.38
Secured Loans
4,299.97
3,214.07
2,483.75
3,383.54
2,622.14
2,339.16
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
94.31
48.66
32.32
275.97
145.34
6.78
Current Liabilities
4,874.74
3,850.56
4,369.30
3,851.04
3,118.01
2,590.70
Trade Payables
2,479.11
1,533.77
1,538.37
1,192.71
1,026.35
917.94
Other Current Liabilities
1,478.61
1,184.72
1,575.68
1,305.30
1,242.76
1,140.63
Short Term Borrowings
747.80
995.32
1,171.38
1,302.29
658.76
360.52
Short Term Provisions
169.22
136.75
83.87
50.74
190.14
171.61
Total Liabilities
17,566.77
15,368.75
14,925.31
14,436.54
12,717.19
10,756.08
Net Block
8,683.96
8,133.43
7,989.93
7,468.60
6,879.18
6,105.49
Gross Block
14,904.70
13,117.63
12,137.48
10,842.12
9,510.49
8,173.25
Accumulated Depreciation
6,213.64
4,984.20
4,147.55
3,373.52
2,631.31
2,067.76
Non Current Assets
10,258.66
9,487.47
9,460.84
9,593.07
8,565.30
7,006.96
Capital Work in Progress
1,099.79
976.90
1,115.80
1,418.58
1,172.34
626.65
Non Current Investment
305.01
271.09
240.26
211.87
216.77
122.67
Long Term Loans & Adv.
155.18
91.08
114.85
493.98
296.97
152.11
Other Non Current Assets
14.72
14.97
0.00
0.04
0.04
0.04
Current Assets
7,308.11
5,881.28
5,464.47
4,843.47
4,151.89
3,749.12
Current Investments
131.78
19.56
144.69
427.11
50.40
0.00
Inventories
3,064.44
2,312.70
2,175.88
1,681.37
1,388.80
1,232.00
Sundry Debtors
2,157.67
2,349.52
2,134.43
1,799.34
1,785.28
1,574.94
Cash & Bank
1,223.64
501.46
482.56
307.56
328.99
405.62
Other Current Assets
730.58
134.87
81.93
140.24
598.42
536.56
Short Term Loans & Adv.
585.78
563.17
444.98
487.85
504.76
395.55
Net Current Assets
2,433.37
2,030.72
1,095.17
992.43
1,033.88
1,158.42
Total Assets
17,566.77
15,368.75
14,925.31
14,436.54
12,717.19
10,756.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
1,652.60
892.30
1,004.54
483.89
766.42
597.58
PBT
-233.26
341.71
119.80
-160.56
441.03
639.68
Adjustment
1,569.45
1,372.66
1,275.88
1,135.53
787.10
721.99
Changes in Working Capital
526.56
-487.72
-234.30
-302.08
-292.29
-619.58
Cash after chg. in Working capital
1,862.75
1,226.65
1,161.38
672.89
935.84
742.09
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-210.15
-334.35
-156.84
-189.00
-169.42
-144.51
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-826.03
-477.46
-434.01
-1,338.78
-1,812.10
-4,479.93
Net Fixed Assets
-236.03
-285.13
-319.07
-350.70
-1,249.33
Net Investments
-474.29
-1,397.15
38.83
-117.46
-38.01
Others
-115.71
1,204.82
-153.77
-870.62
-524.76
Cash from Financing Activity
-38.98
-440.83
-422.36
817.79
794.19
3,976.83
Net Cash Inflow / Outflow
787.59
-25.99
148.17
-37.10
-251.49
94.48
Opening Cash & Equivalents
182.32
219.19
53.23
85.18
261.97
151.95
Closing Cash & Equivalent
976.26
182.32
219.19
53.23
85.18
261.97

Financial Ratios

Standalone /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
60.96
60.88
59.59
55.44
55.15
56.35
ROA
-1.98%
0.60%
0.12%
-1.37%
3.20%
7.76%
ROE
-4.04%
1.14%
0.24%
-2.77%
6.11%
14.90%
ROCE
1.24%
6.61%
5.07%
1.95%
7.10%
13.06%
Fixed Asset Turnover
0.75
0.84
0.82
0.80
0.83
0.77
Receivable days
78.20
77.05
76.20
80.70
83.94
91.03
Inventory Days
93.30
77.13
74.72
69.11
65.47
71.21
Payable days
226.14
173.49
168.73
149.81
144.76
162.72
Cash Conversion Cycle
-54.64
-19.30
-17.80
0.00
4.65
-0.47
Total Debt/Equity
0.68
0.59
0.58
0.81
0.60
0.52
Interest Cover
0.48
1.98
1.40
0.65
3.45
6.81

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022

News Update:


  • Piramal Pharma gets EIR from USFDA for Telangana manufacturing facility
    18th May 2026, 12:38 PM

    The receipt of said EIR marks successful closure of the inspection

    Read More
  • USFDA concludes GMP inspection at Piramal Pharma’s Sellersville facility
    11th May 2026, 09:42 AM

    At the conclusion of the inspection, USFDA issued a Form-483, with three observations

    Read More
  • Piramal Pharma posts Rs 8.82 crore consolidated net loss in Q4FY26
    29th Apr 2026, 11:09 AM

    Consolidated total income of the company increased by 0.06% at Rs 2,797.83 crore for Q4FY26

    Read More
  • Piramal Pharma gets EIR with VAI for USA manufacturing facility
    13th Apr 2026, 11:48 AM

    The receipt of said EIR marks successful closure of the inspection

    Read More
  • Piramal Pharma’s arm completes acquisition of ‘Kenalog’
    1st Apr 2026, 18:25 PM

    Piramal Critical Care B.V. has successfully completed the acquisition of ‘Kenalog’ from Bristol-Myers Squibb Company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.